BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tung I, Sahu A. Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions. Front Oncol 2021;11:707214. [PMID: 34527581 DOI: 10.3389/fonc.2021.707214] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Magee DE, Helstrom E, Kutikov A. The role of cytoreductive nephrectomy in the immuno-oncological therapy era. Curr Opin Urol 2023;33:136-41. [PMID: 36710594 DOI: 10.1097/MOU.0000000000001077] [Reference Citation Analysis]
2 Park H, Kim S, Keam B, Chung H, Seok SH, Kim S, Kim M, Kim TM, Doh J, Kim D, Heo DS. Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-16766-3] [Reference Citation Analysis]
3 Ong HTM, Kim TH, Ates E, Pyun JC, Kang MJ. Overexpression of CYP11A1 recovers cell cycle distribution in renal cell carcinoma Caki-1. Cancer Cell Int 2022;22:299. [PMID: 36182900 DOI: 10.1186/s12935-022-02726-4] [Reference Citation Analysis]
4 Asano Y, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Igarashi K, Higuchi T, Taniguchi Y, Morinaga S, Horimoto T, Nakai M, Kadono Y, Nojima T, Tsuchiya H. Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors. Front Immunol 2022;13:980456. [DOI: 10.3389/fimmu.2022.980456] [Reference Citation Analysis]
5 Kalkusova K, Smite S, Darras E, Taborska P, Stakheev D, Vannucci L, Bartunkova J, Smrz D. Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors. IJMS 2022;23:11080. [DOI: 10.3390/ijms231911080] [Reference Citation Analysis]
6 Rizzo A, Dall'Armellina S, Pizzuto DA, Perotti G, Zagaria L, Lanni V, Treglia G, Racca M, Annunziata S. PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor? Cancers (Basel) 2022;14:4039. [PMID: 36011032 DOI: 10.3390/cancers14164039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Ozaniak A, Smetanova J, Bartolini R, Rataj M, Capkova L, Hacek J, Fialova M, Krupickova L, Striz I, Lischke R, Bartunkova J, Strizova Z. A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockade. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04292-8] [Reference Citation Analysis]
8 Fujiwara R, Kageyama S, Yuasa T. Developments in personalized therapy for metastatic renal cell carcinoma. Expert Review of Anticancer Therapy. [DOI: 10.1080/14737140.2022.2075347] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Drevinskaite M, Dadoniene J, Miltiniene D, Patasius A, Smailyte G. Association between Androgen Deprivation Therapy and the Risk of Inflammatory Rheumatic Diseases in Men with Prostate Cancer: Nationwide Cohort Study in Lithuania. J Clin Med 2022;11:2039. [PMID: 35407647 DOI: 10.3390/jcm11072039] [Reference Citation Analysis]
10 Jasinski-Bergner S, Eckstein M, Taubert H, Wach S, Fiebig C, Strick R, Hartmann A, Seliger B. The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors. Front Immunol 2022;13:811200. [PMID: 35185904 DOI: 10.3389/fimmu.2022.811200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Urso L, Castello A, Rocca GC, Lancia F, Panareo S, Cittanti C, Uccelli L, Florimonte L, Castellani M, Ippolito C, Frassoldati A, Bartolomei M. Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol 2022. [PMID: 35217902 DOI: 10.1007/s00432-022-03958-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Coco D, Leanza S. Von Hippel-Lindau Syndrome: Medical Syndrome or Surgical Syndrome? A Surgical Perspective. J Kidney Cancer VHL 2022;9:27-32. [PMID: 34963877 DOI: 10.15586/jkcvhl.v9i1.206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Liu L, Du X, Fang J, Zhao J, Guo Y, Zhao Y, Zou C, Yan X, Li W. Development of an Interferon Gamma Response-Related Signature for Prediction of Survival in Clear Cell Renal Cell Carcinoma. J Inflamm Res 2021;14:4969-85. [PMID: 34611422 DOI: 10.2147/JIR.S334041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]